These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 6995285)

  • 41. Nitrofurantoin resistance mechanism and fitness cost in Escherichia coli.
    Sandegren L; Lindqvist A; Kahlmeter G; Andersson DI
    J Antimicrob Chemother; 2008 Sep; 62(3):495-503. PubMed ID: 18544599
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An outbreak of heat-stable enterotoxin-producing Escherichia coli O25:HNM resistant to nalidixic acid caused by ingestion of contaminated box-lunch in September-October 2002 in Hyogo and Shiga Prefectures.
    Tsuji H; Oshima K; Hamada K; Ishikawa K; Hayashi K
    Jpn J Infect Dis; 2002 Dec; 55(6):205-6. PubMed ID: 12606831
    [No Abstract]   [Full Text] [Related]  

  • 43. Streptomycin and nalidixic acid elevate the spontaneous genome-wide mutation rate in Escherichia coli.
    Ozdemirel HO; Ulusal D; Kucukyildirim Celik S
    Genetica; 2021 Feb; 149(1):73-80. PubMed ID: 33502702
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nalidixic acid-induced protein alterations in Escherichia coli.
    Chao L
    Antimicrob Agents Chemother; 1977 Jan; 11(1):167-70. PubMed ID: 319748
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hemolysin production in Escherichia coli associated with nalidixic acid resistance.
    Walton JR; Smith DH
    Antimicrob Agents Chemother (Bethesda); 1968; 8():54-6. PubMed ID: 4898540
    [No Abstract]   [Full Text] [Related]  

  • 46. Nalidixic acid-resistant Salmonella typhi in Mumbai.
    Rodrigues C; Mehta A; Joshi VR
    Natl Med J India; 1999; 12(2):88. PubMed ID: 10416332
    [No Abstract]   [Full Text] [Related]  

  • 47. Increasing incidence of quinolone resistance in human non-typhoid Salmonella enterica isolates in Korea and mechanisms involved in quinolone resistance.
    Choi SH; Woo JH; Lee JE; Park SJ; Choo EJ; Kwak YG; Kim MN; Choi MS; Lee NY; Lee BK; Kim NJ; Jeong JY; Ryu J; Kim YS
    J Antimicrob Chemother; 2005 Dec; 56(6):1111-4. PubMed ID: 16244086
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Activity of faropenem and imipenem for ciprofloxacin-resistant bacteria.
    Piddock LJ; Johnson MM; Webber MA
    J Antimicrob Chemother; 2003 Sep; 52(3):500-2. PubMed ID: 12917244
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of R-factor plasmids on host-cell responses to nalidixic acid I. Increased susceptibility of nalidixic acid-sensitive hosts.
    Crumplin GC; Smith JT
    J Antimicrob Chemother; 1981 Apr; 7(4):379-88. PubMed ID: 7019186
    [No Abstract]   [Full Text] [Related]  

  • 50. Low selection of topoisomerase mutants from strains of Escherichia coli harbouring plasmid-borne qnr genes.
    Cesaro A; Bettoni RR; Lascols C; Mérens A; Soussy CJ; Cambau E
    J Antimicrob Chemother; 2008 May; 61(5):1007-15. PubMed ID: 18325893
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence of antimicrobial resistance and resistance genes in faecal Escherichia coli isolates recovered from healthy pets.
    Costa D; Poeta P; Sáenz Y; Coelho AC; Matos M; Vinué L; Rodrigues J; Torres C
    Vet Microbiol; 2008 Feb; 127(1-2):97-105. PubMed ID: 17870255
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antimicrobial agents. II. Microbial degradation of nalidixic acid.
    Capek A; Simek A; Turinová J; Tůma J
    Folia Microbiol (Praha); 1969; 14(1):94-5. PubMed ID: 4892134
    [No Abstract]   [Full Text] [Related]  

  • 53. [Antibacterial activity of nalidixic acid (WIN 18320) on various strains of Gram-negative organisms].
    Callao V; Ramos A
    Microbiol Esp; 1966; 19(2):173-82. PubMed ID: 5974262
    [No Abstract]   [Full Text] [Related]  

  • 54. "Reversion" of DNA polymerase-deficient Escherichia coli.
    D'Alisa RM; Carden GA; Carr HS; Rosenkranz HS
    Mol Gen Genet; 1971; 110(1):23-6. PubMed ID: 4927441
    [No Abstract]   [Full Text] [Related]  

  • 55. Resistance to ultraviolet-induced mutagenesis in Proteus.
    Schwarzhoff R; Santhanam U
    Experientia; 1981; 37(9):965-6. PubMed ID: 7028504
    [No Abstract]   [Full Text] [Related]  

  • 56. Mutants of Klebsiella pneumoniae resistant to several antibiotics.
    Smith HW
    Nature; 1976 Jan; 259(5541):307-8. PubMed ID: 765837
    [No Abstract]   [Full Text] [Related]  

  • 57. Enhancement by nalidixic acid of the thermal susceptibility of the Ts-7 mutant of Escherichia coli TAU-bar.
    Nishida M; Mishima Y; Kawada J; Yielding KL
    Antimicrob Agents Chemother; 1975 Sep; 8(3):384-6. PubMed ID: 1101825
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adaptive drug resistance in Gram-negative bacteria.
    Dean AC
    Proc R Soc Med; 1971 May; 64(5):534-7. PubMed ID: 5576917
    [No Abstract]   [Full Text] [Related]  

  • 59. [Isolation of Chlamydomonas reinhardtii mutants resistant to nalidixic acid].
    Robreau G; Jensen G; Le Gal Y
    C R Acad Hebd Seances Acad Sci D; 1973 Oct; 277(16):1699-702. PubMed ID: 4204876
    [No Abstract]   [Full Text] [Related]  

  • 60. Antibacterially active substances. IV. Microbial hydroxylation of nalidixic acid.
    Capek A; Simek A; Svátek E; Budĕsínský M
    Folia Microbiol (Praha); 1969; 14(6):557-9. PubMed ID: 4906620
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.